Viking Therapeutics (VKTX) Consolidated Net Income (2014 - 2026)

Viking Therapeutics (VKTX) has 13 years of Consolidated Net Income data on file, last reported at -$266.4 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 119.6% year-over-year to -$266.4 million; the trailing twelve-month figure through Mar 2026 stood at -$869.3 million (down 1.47% YoY), and the FY2025 full-year result was -$506.2 million, down 60.63% from the prior year.
• Consolidated Net Income grew to -$266.4 million in Q1 2026, from -$278.7 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$17.8 million in Q3 2022 to a low of -$60.3 billion in Q1 2023.
• A 5-year average of -$8.0 billion and a median of -$189.8 million in 2024 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income slumped 318707.31% in 2023 and jumped 99.48% in 2024, its largest moves.
• Tracing VKTX's Consolidated Net Income over 5 years: stood at -$40.3 million in 2022, then plunged by 126.06% to -$91.1 million in 2023, then sank by 108.42% to -$189.8 million in 2024, then slumped by 46.87% to -$278.7 million in 2025, then advanced by 4.44% to -$266.4 million in 2026.
• Business Quant data shows VKTX's Consolidated Net Income at -$266.4 million in Q1 2026, -$278.7 million in Q4 2025, and -$173.0 million in Q3 2025.